Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 105

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 105
---
 the year ended December                   
 31, 2024, filed with the SEC on April 11, 2025).                                                                                                    |
| 21.1   |     | Subsidiaries                                                                                                                                        
 of Biodexa Pharmaceuticals PLC (incorporated by reference to Exhibit 8.1 of the Company’s Annual Report on Form 20-F for the                        
 year ended December 31, 2024, filed with the SEC on April 11, 2025).                                                                                |
| 23.1^  |     | Consent of PKF Littlejohn LLP, independent registered public accounting firm.                                                                       |
| 23.2^  |     | Consent of Forvis Mazars LLP, independent registered public accounting firm.                                                                        |
| 23.3*  |     | Consent of Brown Rudnick LLP (included in Exhibit 5.1).                                                                                             |
| 24.1*  |     | Powers of Attorney (included on signature page to initial Registration Statement and Post-Effective Amendment No. 1 to the Registration Statement). |
| 97.1   |     | Clawback                                                                                                                                            
 Policy (incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 20-F for the year ended December 31,                       
 2023, filed with the SEC on April 19, 2024).                                                                                                        |
| 107*   |     | Filing Fee Table.                                                                                                                                   |

________________

| ^ | Filed herewith. |

| * | Previously filed. |

| 

# | Management contract or compensatory plan or arrangement. |
| † | Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material 
 and would likely cause competitive harm to Biodexa Pharmaceuticals PLC if publicly disclosed.             |

<div align='center'>59</div>